Literature DB >> 17662007

Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis.

U Ljøstad1, T Skarpaas, A Mygland.   

Abstract

The aim of the study was to examine diagnostic sensitivity and temporal course of intrathecal Borrelia burgdorferi (Bb) antibody production in acute Lyme neuroborreliosis (LNB). We recruited consecutive adult patients with LNB diagnosis based on strict selection criteria. Serum and cerebrospinal fluid (CSFs) were obtained, and clinical examination was performed pre-treatment, and 13 days and 4 months post-treatment. Pre-treatment positive Bb antibody index (AI) was detected in 34 of 43 (79%). All nine pre-treatment Bb AI negative patients, and 26 of 34 pre-treatment Bb AI positive patients reported symptom duration <6 weeks. Eight patients, all Bb AI positive, reported symptom duration of 6 weeks or longer. Consequently, pre-treatment diagnostic sensitivity of Bb AI was 74% when symptom duration was <6 weeks, and 100% when 6 weeks or longer. Three patients converted from negative to positive Bb AI status post-treatment. The six patients who were persistently Bb AI negative had lower CSF cell count and protein at presentation, when compared with the patients with positive Bb AI. In conclusion, the diagnostic sensitivity of Bb AI is suboptimal in acute early LNB. Repeated post-treatment Bb AI testing, to confirm or reject LNB diagnosis, is unreliable, as the majority of initial Bb AI negative patients remained negative at follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662007     DOI: 10.1111/j.1468-1331.2007.01799.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  32 in total

1.  Acute transverse myelitis in Lyme neuroborreliosis.

Authors:  S Bigi; C Aebi; C Nauer; S Bigler; M Steinlin
Journal:  Infection       Date:  2010-05-27       Impact factor: 3.553

2.  Humoral immune responses in patients with Lyme neuroborreliosis.

Authors:  Tjasa Cerar; Katarina Ogrinc; Franc Strle; Eva Ruzić-Sabljić
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

3.  Intrathecally produced IgG and IgM antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis.

Authors:  Gerold Stanek; Lara Lusa; Katarina Ogrinc; Mateusz Markowicz; Franc Strle
Journal:  Med Microbiol Immunol       Date:  2013-12-23       Impact factor: 3.402

4.  Lyme Neuroborreliosis.

Authors:  Sebastian Rauer; Stefan Kastenbauer; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Rick Dersch
Journal:  Dtsch Arztebl Int       Date:  2018-11-09       Impact factor: 5.594

5.  Clinical Reasoning: A 20-year-old man with headache and double vision.

Authors:  Khaled Moussawi; Anoopum Gupta; Haatem Reda
Journal:  Neurology       Date:  2016-10-11       Impact factor: 9.910

6.  Direct Molecular Detection and Genotyping of Borrelia burgdorferi Sensu Lato in Cerebrospinal Fluid of Children with Lyme Neuroborreliosis.

Authors:  Bjørn Barstad; Hanne Quarsten; Dag Tveitnes; Sølvi Noraas; Ingvild S Ask; Maryam Saeed; Franziskus Bosse; Grete Vigemyr; Ilka Huber; Knut Øymar
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

7.  Seronegative lyme neuroborreliosis in a patient using rituximab.

Authors:  Willemijn Alexandra van Dop; Marie-José Kersten; Bob de Wever; Joppe Willem Hovius
Journal:  BMJ Case Rep       Date:  2013-02-14

8.  CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.

Authors:  Unn Ljøstad; Ase Mygland
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

Review 9.  Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature.

Authors:  Nathalie D van Burgel; Mayke Oosterloo; Frank P Kroon; Alje P van Dam
Journal:  BMC Neurol       Date:  2010-11-30       Impact factor: 2.474

Review 10.  Lyme neuroborreliosis-epidemiology, diagnosis and management.

Authors:  Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.